Logo for Pila Pharma

Pila Pharma Investor Relations Material

Latest events

Logo for Pila Pharma

Investor Update

Pila Pharma
Logo for Pila Pharma

Investor Update

28 Oct, 2024
Logo for Pila Pharma

Q2 2024

27 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Pila Pharma

Access all reports
PILA PHARMA AB (publ) is a clinical stage pharmaceutical company developing XEN-D0501, a TRPV1 antagonist targeting the prevention and treatment of type 2 diabetes. The product candidate has completed two phase 2a clinical trials. Once it completes its ongoing phase 2b trial, PILA PHARMA AB (publ) is planning to initiate pivotal phase 3 study.